# Supplementary Information A Physiologically-Based Pharmacokinetic Model for Tuberculosis Drug Disposition at Extrapulmonary Sites

Aparna Ramachandran and Chetan J. Gadgil<sup>\*</sup>

### **1. PBPK Model Equations**

Venous blood:

$$V_V \frac{dC_V}{dt} = \sum_T (Q_T * C_{VT}) + (L_{LN} * C_{VLN}) - Q_C * C_V$$

Arterial blood:

$$V_A \frac{dC_A}{dt} = (Q_C - L_{Lu}) * C_{VLu} - (Q_C - L_{Lu}) * C_A$$

Lungs:

$$V_{Lu}\frac{dC_{Lu}}{dt} = Q_C * C_V - (Q_C - L_{Lu}) * C_{VLu} - (L_{Lu} - Q_{Pl}) * C_{VLu} - Q_{Pl} * C_{VLu}$$

Pleura:

$$V_{Pl}\frac{dC_{Pl}}{dt} = Q_{Pl} * C_{VLu} - Q_{Pl} * C_{Pl}$$

Non-eliminating tissues/organs with afferent lymph (Brain, Heart, Adipose, Muscle, Skin, Others):

$$V_T \frac{dC_T}{dt} = Q_T * C_A - (Q_T - L_T) * C_{VT} - L_T * C_{VT}$$

Non-eliminating tissues/organs without afferent lymph (Bone, Spleen):

$$V_T \frac{dC_T}{dt} = Q_T * C_A - Q_T * C_{VT}$$

Kidney:

$$V_{Kd} \frac{dC_{Kd}}{dt} = Q_{Kd} * C_A - (Q_{Kd} - L_{Kd}) * C_{VKd} - L_{Kd} * C_{VKd} - f_R * CL * C_A$$

Gut:

$$V_{Gu}\frac{dC_{Gu}}{dt} = Q_{Gu} * C_A - (Q_{Gu} - L_{Gu}) * C_{VGu} - L_{Gu} * C_{VGu} + k_a * A_D + k_r * A_{GL}$$

Liver:

$$V_{Li}\frac{dC_{Li}}{dt} = Q_{LA} * C_A + (Q_{Sp} - L_{Sp}) * C_{VSp} + (Q_G - L_G) * C_{VG} - (Q_{Li} - L_{Li}) * C_{VLi} - L_{Gu} \\ * C_{VGu} - (1 - f_R) * CL * \frac{Q_{LA} * C_A + Q_{Sp} * C_{Sp} + Q_G * C_G}{Q_{Li}}$$

Gut Lumen (GL):

$$\frac{dA_{GL}}{dt} = (1 - f_R) * CL * \frac{Q_{LA} * C_A + Q_{Sp} * C_{Sp} + Q_G * C_G}{Q_{Li}} - k_r * A_{GL} - k_F * A_{GL}$$

Lymph Node:

$$V_{LN}\frac{dC_{LN}}{dt} = \sum_{T} (L_T * C_{VT}) - L_{LN} * C_{VLN}$$

Here,  $Q_T$  (L/hr) is the flow rate to and from a tissue/organ "T",  $L_T$  (L/hr) is the lymph flow rate from tissue/organ "T",  $C_A$  (µg/mL) is the drug concentration in arterial blood,  $Q_{Pl}$  is the flow rate of the pleura, *CL* (L/hr) is total systemic clearance of the drug,  $F_T$  is the fraction of total clearance apportioned to T (if any), and  $C_{VT}$  (µg/mL) is the drug concentration exiting T with  $C_{VT} = C_T/P_T$ , where  $P_T$  is the tissue:blood partition co-efficient for T. Amount of drug in tissue T is  $A_T = C_T^*V_T$ , where  $V_T$  is the volume of T.

### 2. Objective Function Used for Minimization to Estimate Parameters

Least squares method is used by the *fitnlm* function during model calibration. Hence, the sum of squares of the offsets of experimental data points from the model simulated concentration curve is minimised, where we assign weight to certain data points. This function for *n* reported data points is:

$$\sum_{i=1}^{n} w_i (y_i - f(x_i))^2$$

 $y_i$  is the measured value of the dependent variable,  $f(x_i)$  is the model predicted value and  $w_i$  is the weight assigned to i<sup>th</sup> observation. The values assigned for  $w_i$  are listed in Table S6.

### **3.** Lymph Node Compartment

To our knowledge, the integration of a lymph node compartment is a novel addition to the study of tuberculosis using PBPK. Many studies have incorporated a lymph node compartment in their PBPK model to evaluate the pharmacokinetics of different substances such as peptides<sup>1</sup>, monoclonal antibodies<sup>2,3</sup>, nanoparticles<sup>4,5</sup> as well as small molecules<sup>6</sup>. A recent PBPK study based on non-human primates has demarcated the lymph node network into five major regions, which then drain into the thoracic duct<sup>7</sup>.

# **4.** Relation of Pyrazinamide Activity to Environmental pH and its Effect on Treatment

Environmental pH has been seen to play an important role in the sterilizing activity of pyrazinamide. Pyrazinamide's anti-bacterial activity has been shown to increase with decreasing pH values<sup>8</sup>. Pyrazinamide is thought to target non- or slowlyreproducing bacteria in acidic compartments such as the macrophage phagosome<sup>9,10</sup>. While immature phagosomes have a pH of 6.2, post bacilli internalization by macrophage, acidification occurs, resulting in a phagosomal pH of pH 4.5 to 5.0<sup>11</sup>. However, this notion is contradicted by the finding that macrophage vesicles containing *M. Tuberculosis* bacteria were not acidic<sup>12</sup>. It has also been suggested that the drug exhibits antimicrobial activity against extracellular slow-replicating bacteria in the epithelial lining fluid<sup>13</sup>. Poor treatment response to pyrazinamide in animal infection models such as mice and guinea pigs, with neutral to alkaline lesion pH, provide further evidence in favour of the enhanced activity of the drug in acidic conditions<sup>10,11</sup>. This observed higher pH in TB lesions in guinea pig and murine models does not appear to be an impediment to treatment with pyrazinamide in humans though, as shown in a study by Kempker et al. where a majority of the lesion samples studied by them (8 out of 10 patients) had an acidic pH ( $\leq 5.5$ )<sup>14</sup>. As stated by Srivastava et al., pH in human TB cavities varies around 5.5, while that in murine TB models is higher<sup>15</sup>. This is a probable cause for differential outcomes in the two cases.

## 5. Supplementary Tables

**Table S1<sup>†</sup>:** A summary of relevant whole-body PBPK models for adults incorporating anti-TB drugs

|   | Drug                      | Type of TB | Features of the Model  | References |
|---|---------------------------|------------|--|------------|
| 1 | Isoniazid                 | Pulmonary  | <ul> <li>Describes NAT2-dependent<br/>pharmacokinetics of isoniazid and<br/>its metabolites</li> <li>Includes acetylator status (fast,<br/>intermediate, slow)</li> <li>Includes PD</li> </ul>   | 17         |
| 2 | Isoniazid                 | Pulmonary  | <ul> <li>Employs two coupled PBPK models:<br/>one for a lactating mother and one<br/>for her infant to study drug<br/>exposure in the infant from drug<br/>intake by the mother</li> <li>Includes acetylator status (fast and<br/>slow)</li> </ul> | 18         |
| 3 | Isoniazid                 | Pulmonary  | <ul> <li>Assessment of potential drug-drug<br/>interactions with CYP2C19 and<br/>CYP3A4 substrates</li> <li>Includes acetylator status (fast and<br/>slow)</li> </ul>  | 19         |
| 4 | Ethambutol                | Pulmonary  | <ul> <li>Considers scenarios that reflect<br/>different stages of PBPK model<br/>development to evaluate drug<br/>pharmacokinetics</li> </ul>  | 20         |
| 5 | Rifampicin                | Pulmonary  | <ul> <li>Recognizes and models differences<br/>in rifampicin pharmacokinetics after<br/>a single dose in healthy, TB and<br/>cirrhosis populations</li> </ul>  | 21         |
| 6 | Rifampicin,<br>Ethambutol | Pulmonary  | <ul> <li>Structured model with two<br/>organisms: lactating mother and<br/>nursing infant</li> </ul>   | 23         |

<sup>&</sup>lt;sup>+</sup> In these models, human physiology is described by representing organs and tissues as compartments. The number of compartments varies, depending on the modelling approach adopted. Each compartment can be homogenous and well-stirred or consist of sub-compartments. A notable exception is the representation of the lung as a multi-compartment permeability-limited organ<sup>16</sup>. These PBPK studies simulate the time-dependent concentrations of a single drug<sup>17–22</sup>, as well as multiple drugs<sup>16,23–26</sup>, for first-line and many second- and third-line anti-TB drugs. The models that study first-line drugs do not include EPTB sites as their focus is pulmonary TB. To our knowledge, only one study models EPTB treatment through a PBPK model<sup>22</sup>.

| 7  | Rifampicin,<br>Isoniazid,<br>Pyrazinamide,<br>Ethambutol  | Pulmonary  | • | Properties predicted from mice<br>were used to deduce parameters<br>and predict lung:plasma ratio in<br>humans which were compared to<br>biopsy data from patients | 24 |
|----|---|--|---|--|----|
| 8  | Delamanid,<br>Isoniazid,<br>Rifapentine   | Pulmonary  | • | administration of select anti-TB<br>drugs for LTBI treatment<br>Includes acetylator status   |    |
| 9  | Delamanid   | Pulmonary<br>and Extra-<br>pulmonary<br>(Brain,<br>Heart, Liver) | • | Simulated concentrations of the<br>drug in the lung, brain, liver, and<br>heart and found them to be higher<br>than the estimated effective<br>concentration       | 22 |
| 10 | Rifampicin,<br>Ethambutol,<br>Isoniazid,<br>Itraconazole,<br>Erythromycin,<br>Clarithromycin,<br>Pyrazinamide                                       | Pulmonary<br>(Lungs)   | • | Incorporates a multi-compartment<br>permeability-limited lung<br>model instead of a single<br>homogeneous lung compartment   | 16 |
| 11 | Bedaquiline,<br>Clofazimine,<br>Cycloserine,<br>Isoniazid<br>Ethambutol,<br>Ethionamide,<br>Kanamycin,<br>Pyrazinamide,<br>Rifampicin,<br>Linezolid | Pulmonary<br>(Lungs)   | • | Model accuracy assessed using drug<br>plasma concentrations and lung<br>tissue concentrations  | 26 |

**Table S2:** Physiological parameters for the assumed male individual

| Parameter                | Value                  | References |
|--------------------------|------------------------|------------|
| Body weight              | 70 kg                  | Assumption |
| Cardiac output           | 5200 mL/min            | 27         |
| Afferent lymph flow rate | 8 L/day                | 28         |
| Gut lumen transit rate   | 0.252 hr <sup>-1</sup> | 29         |

| Organ/Tissue   | Symbol          | <b>Volume</b> <sup>2,27,30</sup> | Blood Flow                                  | Lymph Flow Rate <sup>31</sup> |
|----------------|-----------------|----------------------------------|---|-------------------------------|
|                |                 | (as fraction of                  | Rate <sup>27,29</sup>                       | (as fraction of               |
|                |                 | Body Weight)                     | (as fraction of                             | Afferent Lymph                |
|                |                 |                                  | Cardiac Output)                             | Flow)                         |
| Lungs          | Lu              | 0.0076                           | -   | 0.03                          |
| Brain          | Br              | 0.02                             | 0.12  | 0.0105                        |
| Adipose        | Ad              | 0.2142 <sup>a</sup>              | 0.05  | 0.128                         |
| Heart          | Hr              | 0.0047                           | 0.04  | 0.01                          |
| Muscle         | Mu              | 0.4                              | 0.17  | 0.16                          |
| Bone           | Во              | 0.1429 <sup>a</sup>              | 0.05  | 0                             |
| Skin           | Sk              | 0.0371                           | 0.05  | 0.0703                        |
| Kidney         | Kd              | 0.0044                           | 0.19  | 0.085                         |
| Spleen         | Sp              | 0.0026                           | 77/5200 <sup>e</sup>                        | 0                             |
| Gut            | Gu              | 0.0171                           | 1100/5200 <sup>e</sup>                      | 0.12                          |
| Liver          | Li              | 0.0257                           | $Q_{LA} + Q_{Gu} + Q_{Sp}$                  | 0.33                          |
| Hepatic Artery | LA              | -                                | 0.06  | -                             |
| Lymph Node     | LN              | 0.274/70 <sup>b</sup>            | -   | -                             |
| Arterial Blood | А               | 1.8/70 <sup>c</sup>              | -   | -                             |
| Venous Blood   | V               | 3.6/70 <sup>c</sup>              | -   | -                             |
| Others         | Oth             | 0.04264 <sup>d</sup>             | 0.04365 <sup>f</sup>                        | 0.0562 <sup>g</sup>           |
| Pleura         | Q <sub>Pl</sub> | 0.3 mL kg <sup>-1*32</sup>       | 0.15 mL kg <sup>-1</sup> h <sup>-1*32</sup> | -                             |

Table S3: Tissue-wise physiological parameters values

a: Density = Mass/Volume. We assume that Density  $\approx 1 \text{ g/cm}^3$  and so Mass  $\approx$  Volume, except for adipose where density = 0.916 g/cm<sup>3</sup> and for bone where density = 1.92 g/cm<sup>3</sup>

b: Taken from Shah & Betts, 2012 (Combined volume of LNs = 274 mL)

c: Taken from Igari et al. (Volume of arterial blood = 1.8 L, venous blood = 3.6 L)

d: Others = 1 - (Sum of other compartments) = 1 - 0.9576 = 0.0424

e: Taken from Davies & Morris, 1993

f: Others = 1 - (Sum of other compartments) = 1 - 0.95635 = 0.04365 (Pleura fraction is considered negligible)

g: Others = 1 - (Sum of other compartments) = 1 - 0.9438 = 0.0562

|                   | Rifampicin               | Ethambutol                  | Isoniazid                | <b>Pyrazinamide</b> <sup>a</sup> |
|-------------------|--------------------------|-----------------------------|--------------------------|----------------------------------|
| Compound type     | Zwitterion <sup>33</sup> | Diprotic base <sup>34</sup> | Monoprotic               | Neutral <sup>34</sup>            |
|                   | (group 1)                |                             | base <sup>34</sup>       |                                  |
| Acid dissociation | pKa1 = 1.7,              | pKa1 = 6.5,                 | 1.82 <sup>34</sup>       | 0.5 <sup>35</sup>                |
| constant (pKa)    | рКа2 = 7.9 <sup>33</sup> | рКа2 = 9.55 <sup>34</sup>   |                          |                                  |
| logPo:w           | 2.7 <sup>33</sup>        | -0.3 <sup>36</sup>          | -0.7 <sup>37</sup>       | -0.6 <sup>35</sup>               |
| logPvo:w          | 1.7                      | -1.7                        | -2.1                     | -2                               |
| BP                | 0.9 <sup>38</sup>        | 0.99#                       | 1*                       | 1*                               |
| Кри <sub>вс</sub> | 5.19                     | 1.30 <sup>39</sup>          | 1.33                     | 1.11                             |
| Кавс              | 8.33                     | 1.31                        | -                        | -                                |
| fu                | 0.15 <sup>40</sup>       | 0.75 <sup>34</sup>          | 0.95 <sup>34</sup>       | 0.9 <sup>34</sup>                |
| fR                | 0.07 <sup>41</sup>       | 0.79 <sup>41</sup>          | Fast: 0.07 <sup>42</sup> | 0.09 <sup>41</sup>               |
|                   |                          |                             | Slow: 0.29 <sup>42</sup> | ]                                |

Table S4: Chemical and biological properties of the 4 first-line anti-TB drugs

a: Pyrazinamide is hydrophilic nature<sup>43</sup>. Lipoproteins usually binds with hydrophobic drugs<sup>44</sup>. Hence, it is assumed that pyrazinamide interacts majorly with albumin instead of lipoproteins.

#### logPo:w – n-octanol:water logP

logPvo:w – vegetable oil:water logP is required to estimate adipose tissue Kp and is calculated using the linear regression relationship proposed by Leo et al.<sup>45</sup> between logPo:w and logPvo:w as experimental values were not found. The equation used here is an adaptation of this relationship, by Poulin and Theil<sup>46</sup>, *logPvo:w* = 1.1115 \* *logPo:w* – 1.35

BP – Blood:plasma ratio of the drug

KpuBC – Blood cell:plasma water unbound drug concentration ratio. Is calculated<sup>47</sup> as  $(H - 1 + BP)/(fu^*H)$  where haematocrit H is taken to be 0.45<sup>46</sup>, except for ethambutol for which experimental value is available

 $Ka_{BC} - Ka$  is the association constant of basic/zwitterionic drugs with acidic phospholipids of a tissue.  $Ka_{BC}$  corresponds to Ka for blood cells and is calculated using  $Kpu_{BC}^{48}$ . Ka values for drugs are not available readily and hence are approximated as KaBC.

fu – fraction of drug unbound in the plasma

fR – fractional renal clearance

\*: BP value for isoniazid and pyrazinamide were assumed to be 1. In  $P_T$  calculation, the B:P (blood/plasma partition coefficient) for isoniazid and pyrazinamide have been set to 1 as this experimental data is unavailable in literature. This is based on the reported assumption that for drugs that are distributed homogenously into tissues, B:P can be taken to be  $1^{46}$ .

#: BP value was calculated from KpuBC

| Organ/Tissue        | Rifampicin          | Ethambutol | Isoniazid | Pyrazinamide        |
|---------------------|---------------------|------------|-----------|---------------------|
| Lungs               | 0.9341 <sup>a</sup> | 4.3579     | 0.7662    | 1.3379 <sup>a</sup> |
| Brain               | 0.2290              | 1.8014     | 0.7537    | 0.7184              |
| Adipose             | 0.1890              | 0.4586     | 0.1543    | 0.1503              |
| Heart               | 1.0187              | 3.0400     | 0.7550    | 0.7243              |
| Muscle              | 0.6968              | 2.6942     | 0.7208    | 0.6868              |
| Bone                | 0.3166              | 1.3699     | 0.4330    | 0.4163              |
| Skin                | 0.6282              | 1.9808     | 0.6674    | 0.6497              |
| Kidney              | 2.1789              | 5.2877     | 0.7441    | 0.7127              |
| Spleen              | 1.3990              | 3.9689     | 0.7605    | 0.7260              |
| Gut                 | 1.0812              | 3.1812     | 0.7429    | 0.7140              |
| Liver               | 1.9704              | 5.0521     | 0.7212    | 0.6887              |
| Lymph Node          | 1.2116              | 3.6471     | 0.7556    | 0.7210              |
| Others <sup>b</sup> | 1.0812              | 3.1812     | 0.7441    | 0.7140              |

**Table S5:** Tissue-wise calculated partition coefficient values

a: Calculated by model fitting

b: Median of all other values

|             |                                    |        |        |         |      |               |            |      | Rifa | ampi              | cin   |     |              |             |      |            |             |       |     |       |         |
|-------------|------------------------------------|--------|--------|---------|------|---------------|------------|------|------|-------------------|-------|-----|--------------|-------------|------|------------|-------------|-------|-----|-------|---------|
|             | Acocella                           | a, 197 | '8     |         |      |               |            |      |      |                   |       |     |              |             |      |            |             |       |     |       |         |
|             | 1                                  | 1 2 3  |        |         | 3    | 4             |            |      |      |                   | 5     | 5   |              | 6           |      |            | 7           |       |     | 8     |         |
| Fig. 2      | 0.0238                             | (      | 0.02   | 38      | 0.23 | ).2381        |            | ).02 | 38   |                   | 0.02  | 38  |              | 0.02        | 238  |            | 0.02        | 238   |     | 0.02  | 238     |
| rig. Z      | Furesz, 1970                       |        |        |         |      |               |            |      |      |                   |       |     |              |             |      |            |             |       |     |       |         |
|             | 1                                  |        |        | 2       |      | 3             |            |      |      |                   | 4     |     |              | 5           |      |            |             | 6     |     |       |         |
|             | 0.4763                             |        |        | 0.0238  |      |               | 0.023      | 38   |      |                   | 0.02  | 38  |              |             | 0.02 | 38         |             |       | 0.0 | 0238  |         |
| <b>Г</b> :~ | Prideau                            | x et a | I., 2  | 016     |      |               |            |      |      |                   |       |     |              |             |      |            |             |       |     |       |         |
| rig.<br>co  | 1 2                                |        |        |         | 3    |               |            | 4    |      |                   |       | 5   |              |             | 6    |            |             |       | 7   |       |         |
| 33          | 0.6667 0.0333 0                    |        |        | 0.03    | 33   |               | 0.         | 0333 |      |                   | 0.033 | 33  |              | 0.0         | 333  |            |             | 0.166 | 8   |       |         |
|             |                                    |        |        |         |      |               |            | I    | Etha | ambu              | itol  |     |              |             |      |            |             |       |     |       |         |
|             | Strauch et al., 2011 (Etb-91-400B) |        |        |         |      |               |            |      |      |                   |       |     |              |             |      |            |             |       |     |       |         |
|             | 1                                  | 2 3 4  |        |         | 56   |               | 6          | 7    |      |                   | 8     |     | 9            | 9 1         |      | 10         |             | 11    |     |       |         |
| F: 0        | 0.0208 0.0208 0.0208 0.020         |        |        |         | 020  | 08 0.3128 0.0 |            |      | 0.02 | 208 0.0208 0.0208 |       |     | 0.           | 0.0208 0.20 |      | ).20       | 2083 0.0208 |       |     |       |         |
| Fig. 2      | Strauch et al., 2011 (Etb-ref-400) |        |        |         |      |               |            |      |      |                   |       |     |              |             |      |            |             |       |     |       |         |
|             | 1 2 3                              |        |        |         | 4    |               |            | 5    |      | 6 7               |       |     | 8            |             |      | 9          |             |       | 0   |       |         |
|             | 0.0208                             | 0.0    | 208    | 0.02    | 08   | 0.0           | 208 0.0208 |      | 38   | 0.1045 0.0208 0   |       | 30  | 0.0208 0.020 |             | )20  | .08 0.0208 |             |       |     |       |         |
|             |                                    |        |        | 1       |      | 1             |            | ls   | oni  | iazid             | (FA)  |     |              |             |      |            |             |       |     |       |         |
|             | Gallicano et al., 1994             |        |        |         |      |               |            |      |      |                   |       |     |              |             |      |            |             |       |     |       |         |
| Fig. 2      | 1                                  | 2      |        | 3       | 4    |               | 5          |      | 6    |                   | 7     |     | 8            |             | 9    |            | 10          |       | 11  |       | 12      |
|             | 0.0400                             | 0.40   | 00     | 0.0400  | 0.04 | -00           | 0.040      | 00   | 0.0  | 400               | 0.04  | -00 | 0.04         | 100         | 0.04 | 00         | 0.04        | 400   | 0.0 | 0400  | 0.2000  |
|             |                                    |        |        |         |      |               |            | ls   | oni  | iazid             | (SA)  |     |              |             |      |            |             |       |     |       |         |
|             | Gallican                           | o et a | al., 1 | .994    |      |               |            |      |      |                   |       |     |              |             |      |            |             |       |     |       |         |
| Fig. 2      | 1                                  | 2      | 3      | 4       |      | 5             | 6          |      | 7    |                   | 8     |     | 9            | 10          | )    | 11         |             | 12    |     | 13    | 14      |
|             | 0.0357                             | ).535  | 90.0   | 03570.0 | 3570 | 0.03          | 570.0      | 035  | 70.  | 0357              | 0.03  | 57  | 0.035        | 570.        | 0357 | 0.0        | 357         | 0.03  | 57  | 0.035 | 70.0357 |

Table S6: Weights assigned to different experimental data points during model calibration

Table S7: Predicted PK parameters for each drug

| Drug           |      | Absorption rate,                        | Systemic Clearance,            | Lung tissue : Plasma                   |
|----------------|------|---|--------------------------------|--|
|                |      | <i>k<sub>a</sub></i> (h <sup>-1</sup> ) | <i>CL</i> (L h <sup>-1</sup> ) | Partition Coefficient, P <sub>Lu</sub> |
| Rifampicir     | า    | 0.9095                                  | 9.1130                         | 0.9336                                 |
| Ethambut       | ol   | 0.2221                                  | 50.4888                        | -                                      |
| Isoniazid Fast |      | 2.9895                                  | 24.5171                        | -                                      |
| Slow           |      | 4.1112                                  | 9.1799                         |  |
| Pyrazinam      | nide | 1.5148                                  | 4.3085                         | 1.3798                                 |

## 6. Supplementary Figures

**Figure S1:** Model Calibration – Goodness-of-fit plots for predicted and reported plasma concentrations for oral doses of rifampicin (450 mg), ethambutol (400 mg), isoniazid (300 mg) and pyrazinamide (2000 mg). Concentration vs time predictions are shown in Figure 2.

**Figure S2:** Model Calibration – Curve-fitting predicted lung tissue concentrations rifampicin and pyrazinamide to reported concentrations alongside goodness-of-fit plots for predicted<sup>49</sup> and observed lung tissue concentrations. Oral doses of 600 mg rifampicin and 1500 mg pyrazinamide were administered.

**Figure S3:** Model Validation – Goodness-of-fit plots for predicted and observed drug plasma concentrations in simulations. Oral doses of rifampicin (600 mg), ethambutol (1200 mg), isoniazid (300 mg) and pyrazinamide (1500 mg) were simulated. Concentration vs time predictions are shown in Figure 3.

**Figure S4:** Ratio of time-dependent drug concentrations at different EPTB sites to that in the lung compartment over time. The dashed line indicates a ratio of 1.

## 7. References:

- Offman, E., Phipps, C. & Edginton, A. N. Population physiologically-based pharmacokinetic model incorporating lymphatic uptake for a subcutaneously administered pegylated peptide. *In Silico Pharmacol* 4, 3 (2016).
- Shah, D. K. & Betts, A. M. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39, 67–86 (2012).
- 3. Urva, S. R., Yang, V. C. & Balthasar, J. P. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. *J Pharm Sci* **99**, 1582–1600 (2010).
- Aborig, M. *et al.* Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation. *Pharmaceutics* **11**, 179 (2019).
- 5. Dogra, P. *et al.* A mathematical model to predict nanomedicine pharmacokinetics and tumor delivery. *Comput Struct Biotechnol J* **18**, 518–531 (2020).
- Scholz, E. M. B., Cao, Y. & Kashuba, A. D. M. A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models. *J Antimicrob Chemother* **76**, 2890–2893 (2021).
- Perazzolo, S., Shireman, L. M., Shen, D. D. & Ho, R. J. Y. Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture. *Journal of Pharmaceutical Sciences* **111**, 529–541 (2022).

- Salfinger, M. & Heifets, L. B. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. *Antimicrob Agents Chemother* 32, 1002–1004 (1988).
- 9. Rohde, K., Yates, R. M., Purdy, G. E. & Russell, D. G. Mycobacterium tuberculosis and the environment within the phagosome. *Immunological Reviews* **219**, 37–54 (2007).
- 10. Lamont, E. A. & Baughn, A. D. Impact of the host environment on the antitubercular action of pyrazinamide. *EBioMedicine* **49**, 374–380 (2019).
- 11. Lamont, E. A., Dillon, N. A. & Baughn, A. D. The Bewildering Antitubercular Action of Pyrazinamide. *Microbiol Mol Biol Rev* **84**, e00070-19 (2020).
- 12. Crowle, A. J., Dahl, R., Ross, E. & May, M. H. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. *Infection and Immunity* **59**, 1823–1831 (1991).
- Gumbo, T., Dona, C. S. W. S., Meek, C. & Leff, R. Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs. *Antimicrobial Agents* and Chemotherapy 53, 3197–3204 (2009).
- Kempker, R. R. *et al.* Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis. *Antimicrobial Agents and Chemotherapy* **61**, e00226-17.
- 15. Srivastava, S., Pasipanodya, J. G. & Gumbo, T. pH Conditions under Which Pyrazinamide Works in Humans. *Antimicrobial Agents and Chemotherapy* **61**, e00854-17.
- Gaohua, L. *et al.* Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs. *CPT: Pharmacometrics & Systems Pharmacology* 4, 605–613 (2015).

- 17. Cordes, H. *et al.* A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy. *Antimicrobial Agents and Chemotherapy* **60**, 6134–6145 (2016).
- 18. Garessus, E. D. G., Mielke, H. & Gundert-Remy, U. Exposure of Infants to Isoniazid via Breast Milk After Maternal Drug Intake of Recommended Doses Is Clinically Insignificant Irrespective of Metaboliser Status. A Physiologically-Based Pharmacokinetic (PBPK) Modelling Approach to Estimate Drug Exposure of Infants via Breast-Feeding. *Front Pharmacol* **10**, 5 (2019).
- 19. Balhara, A. & Singh, S. PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid. *Pharm Res* **38**, 1485–1496 (2021).
- Carrara, L. *et al.* Ethambutol disposition in humans: Challenges and limitations of wholebody physiologically-based pharmacokinetic modelling in early drug development. *European Journal of Pharmaceutical Sciences* **150**, 105359 (2020).
- Rasool, M. F. *et al.* Development and Evaluation of Physiologically Based
   Pharmacokinetic Drug–Disease Models for Predicting Rifampicin Exposure in
   Tuberculosis and Cirrhosis Populations. *Pharmaceutics* **11**, 578 (2019).
- Shibata, M. *et al.* Prediction of Human Pharmacokinetic Profiles of the Antituberculosis
   Drug Delamanid from Nonclinical Data: Potential Therapeutic Value against
   Extrapulmonary Tuberculosis. *Antimicrob Agents Chemother* 65, e02571-20.
- Partosch, F., Mielke, H., Stahlmann, R. & Gundert-Remy, U. Exposure of Nursed Infants to Maternal Treatment with Ethambutol and Rifampicin. *Basic & Clinical Pharmacology* & Toxicology 123, 213–220 (2018).
- 24. Muliaditan, M., Teutonico, D., Ortega-Muro, F., Ferrer, S. & Pasqua, O. D. Prediction of lung exposure to anti-tubercular drugs using plasma pharmacokinetic data: implications

for dose selection. *European Journal of Pharmaceutical Sciences* 106163 (2022) doi:10.1016/j.ejps.2022.106163.

- 25. Rajoli, R. K. *et al.* Modeling the long-acting administration of anti-tuberculosis agents using PBPK a proof of concept study. *Int J Tuberc Lung Dis* **22**, 937–944 (2018).
- Humphries, H. *et al.* Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugs. *CPT: Pharmacometrics & Systems Pharmacology* **10**, 1382–1395 (2021).
- Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R. & Beliles, R. P. Physiological parameter values for physiologically based pharmacokinetic models. *Toxicol Ind Health* 13, 407–484 (1997).
- Renkin, E. M. Some consequences of capillary permeability to macromolecules: Starling's hypothesis reconsidered. *American Journal of Physiology-Heart and Circulatory Physiology* 250, H706–H710 (1986).
- 29. Davies, B. & Morris, T. Physiological parameters in laboratory animals and humans. *Pharm Res* **10**, 1093–1095 (1993).
- Igari, Y., Sugiyama, Y., Sawada, Y., Iga, T. & Hanano, M. Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model. J Pharmacokinet Biopharm 11, 577–593 (1983).
- 31. Gill, K. L., Gardner, I., Li, L. & Jamei, M. A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins. AAPS J 18, 156–170 (2016).
- Miserocchi, G. Physiology and pathophysiology of pleural fluid turnover. *European Respiratory Journal* 10, 219–225 (1997).
- 33. PubChem. Rifampicin. https://pubchem.ncbi.nlm.nih.gov/compound/135398735.

- 34. Gaohua, L. *et al.* Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs. *CPT: Pharmacometrics & Systems Pharmacology* **4**, 605–613 (2015).
- 35. PubChem. Pyrazinamide. https://pubchem.ncbi.nlm.nih.gov/compound/1046.
- 36. PubChem. Ethambutol. https://pubchem.ncbi.nlm.nih.gov/compound/14052.
- 37. PubChem. Isoniazid. https://pubchem.ncbi.nlm.nih.gov/compound/3767.
- 38. Loos, U. *et al.* Pharmacokinetics of oral and intravenous rifampicin during chronic administration. *Klin Wochenschr* **63**, 1205–1211 (1985).
- 39. Lee, C. S., Gambertoglio, J. G., Brater, D. C. & Benet, L. Z. Kinetics of oral ethambutol in the normal subject. *Clin Pharmacol Ther* **22**, 615–621 (1977).
- 40. Burman, W. J., Gallicano, K. & Peloquin, C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. *Clin Pharmacokinet* **40**, 327–341 (2001).
- 41. Brunton, L., Knollman, B. & Hilal-Dandan, R. *Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition*. (McGraw Hill Professional, 2017).
- 42. Wilkins, J. J. *et al.* Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. *Br J Clin Pharmacol* **72**, 51–62 (2011).
- 43. Piccaro, G., Poce, G., Biava, M., Giannoni, F. & Fattorini, L. Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis. *The Journal of Antibiotics* **68**, 711–714 (2015).
- 44. Sobansky, M. R. & Hage, D. S. Analysis of Drug Interactions with Lipoproteins by High-Performance Affinity Chromatography. *Adv Med Biol* **53**, 199–216 (2012).
- 45. Leo, A., Hansch, C. & Elkins, D. Partition coefficients and their uses. *Chem. Rev.* **71**, 525–616 (1971).

- 46. Poulin, P. & Theil, F.-P. Prediction of Pharmacokinetics Prior to In Vivo Studies. 1. Mechanism-Based Prediction of Volume of Distribution. *JPharmSci* **91**, 129–156 (2002).
- 47. Rowland, M. & Tozer, T. N. *Clinical Pharmacokinetics: Concepts and Applications*. (Williams & Wilkins, 1995).
- Rodgers, T., Leahy, D. & Rowland, M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. *J Pharm Sci* 94, 1259– 1276 (2005).
- 49. Prideaux, B. *et al.* The association between sterilizing activity and drug distribution into tuberculosis lesions. *Nat Med* **21**, 1223–1227 (2015).